AKAN
Akanda Corp
NASDAQ: AKAN · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$25.99
+48.60% today
Updated 2026-04-29
Market cap
$13.89M
P/E ratio
0.04
P/S ratio
16.60x
EPS (TTM)
$696.80
Dividend yield
—
52W range
$2 – $121
Volume
2.1M
Akanda Corp (AKAN) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $2062.00 | $41431.00 | $2.62M | $2.16M | $836664.00 |
| Revenue growth (YoY) | — | — | +1909.3% | +6223.0% | -17.5% | -61.3% |
| Cost of revenue | $198824.00 | $1809.00 | $756157.00 | $649877.00 | $2.05M | $628282.00 |
| Gross profit | $-198824.00 | $253.00 | $-714726.00 | $3.27M | $111449.00 | $208382.00 |
| Gross margin | — | 12.3% | -1725.1% | 124.8% | 5.2% | 24.9% |
| R&D | — | — | — | — | — | — |
| SG&A | $702411.00 | $1.36M | $5.81M | $19.85M | $5.88M | $4.45M |
| Operating income | $-901235.00 | $-1.67M | $-2.57M | $-20.18M | $-10.05M | $-4.38M |
| Operating margin | — | -80787.3% | -6203.4% | -770.2% | -465.3% | -523.8% |
| EBITDA | $-702010.00 | $-1.41M | $-2.15M | $-4.52M | $-27.74M | $-3.03M |
| EBITDA margin | — | -68218.4% | -5199.4% | -172.6% | -1284.0% | -361.8% |
| EBIT | $-900834.00 | $-1.66M | $-2.46M | $-8.12M | $-32.02M | $-3.17M |
| Interest expense | $493807.00 | $645162.00 | $10509.00 | $115324.00 | $255656.00 | $100107.00 |
| Income tax | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-1.89M | $-2.30M | $-8.13M | $-11.66M | $-32.28M | $-4.10M |
| Net income growth (YoY) | — | -21.8% | -253.4% | -43.4% | -176.9% | +87.3% |
| Profit margin | — | -111569.9% | -19625.9% | -445.0% | -1494.2% | -489.6% |